An ongoing testosterone prescription needs an ongoing clinical relationship. Receiving another shipment does not tell you whether the treatment remains appropriate or whether its risks are being monitored.
Your clinician should explain the checks relevant to your history and product. The points here are selected issues to discuss, not a complete warning list or a schedule for managing yourself.
Know the monitoring plan, the clinician responsible for it, and the route to prompt medical help.
Read the current cardiovascular update accurately
In February 2025, FDA announced removal of boxed-warning language about increased adverse cardiovascular outcomes following its review of the TRAVERSE trial. At the same time, it required labeling changes addressing increased blood pressure.
Those are two different findings. It is inaccurate to turn the update into a statement that testosterone has no cardiovascular concerns or that it is appropriate for healthy people seeking performance benefits. FDA retained limitations concerning age-related hypogonadism. Ask how the current label and your own health history affect the decision.
References: FDA: testosterone labeling changes
Ask what the clinical team will track
The Endocrine Society guideline addresses monitoring response and adverse effects, including testosterone levels and hematocrit, with prostate-related assessment where appropriate. Your clinician should explain the role of each check and the plan for discussing results.
Bring up blood-pressure history, sleep apnea, urinary concerns, and any prior abnormal blood counts. This is not the entire medical screen. Our testing file distinguishes the initial diagnosis from monitoring after treatment starts.
References: Endocrine Society: diagnosis and treatment guideline / Urology Care Foundation: low testosterone
Make fertility and product risks explicit
Testosterone can reduce sperm production. Tell your clinician about current or future plans for children before starting. Do not assume an additional medication in a commercial package guarantees fertility preservation; that is a specialist clinical question.
Topical products also require attention to unintended transfer to other people. Follow the exact product’s instructions for application, handwashing, covering the area, and avoiding exposure. Our formulation comparison explains why everyday handling should be considered before choosing a product.
References: Endocrine Society: diagnosis and treatment guideline / Urology Care Foundation: low testosterone / DailyMed: testosterone gel 1.62% labeling
Decide what happens between appointments
Ask how to report a new symptom, what response time to expect, and where to seek urgent care. Chest pain, signs of stroke, severe breathing difficulty or another emergency need emergency services rather than a routine message. For prescription-specific adverse reactions, consult the medication guide and your clinical team.
Do not change a dose or add another hormone-related medicine using an article. Reassess treatment with the prescriber if benefit is unclear, a safety issue arises, or your circumstances change. Use the appointment brief and cost guide to ask whether that reassessment is included in your agreement.
References: DailyMed: testosterone gel 1.62% labeling / Endocrine Society: diagnosis and treatment guideline / FDA: testosterone labeling changes
Source record
- FDA: testosterone labeling changes
February 2025 update; cardiovascular boxed-warning language and blood-pressure warnings must be distinguished.
- Endocrine Society: diagnosis and treatment guideline
Clinical guidance for men with hypogonadism; not a self-diagnosis tool.
- Urology Care Foundation: low testosterone
Patient education on evaluation, monitoring and fertility. Current FDA update takes precedence for labeling changes.
- DailyMed: testosterone gel 1.62% labeling
Product-specific label. Does not establish safety or equivalence of every compounded formulation.
